---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-002786"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:56:54.168658+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Relmada licenses NDV-01 from Trigone for $3.5M + 3M shares; Phase 2 data at AUA April 2025

## Summary
- Upfront: $3.5M cash + 3,017,420 shares (10% of outstanding) for exclusive worldwide rights (ex-India, Israel, S. Africa).
- Up to $200M in development/regulatory/sales milestones + 3% royalty on net sales.
- NDV-01 is sustained-release gemcitabine/docetaxel for NMIBC; Phase 2 topline data at AUA April 26-29, 2025.
- Shares locked up for 12 months; Trigone must vote as board recommends.
- Relmada must spend ≥$5M/year on R&D/commercialization from 2026; Trigone can terminate if not.

## SEC filing metadata
- accession: 0001013762-25-002786
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000101376225002786/0001013762-25-002786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000101376225002786/ea0235681-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-002786
- JSON: https://secwatch.observer/filing/0001013762-25-002786.json
- Plain text: https://secwatch.observer/filing/0001013762-25-002786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.